Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its acquisition (PDF) ...

After Xoma Royalty went on a dealmaking spree last year, the biotech royalty aggregator is now itself being bought out by its ...

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

Healthcare consumer and OTC brand company Haleon has hired Richard Manso as its new U.S. chief marketing officer. His remit ...

The FDA has taken umbrage with certain Incyte promotional claims related to its chronic graft-versus-host disease (cGVHD) ...

In a brutal first quarter for Roche, key drugs in the company’s pharmaceutical division fall short of Wall Street ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

After a series of regulatory and clinical setbacks for Sanofi’s tolebrutinib, the French pharma has scored a victory for the ...

The FDA has doled out two manufacturing-related complete response letters (CRLs), slamming the brakes on prospective ...

With Regeneron poised to announce a drug pricing deal with the White House Thursday, all 17 companies targeted in a round of ...

The FDA’s new practice of releasing redacted complete response letters (CRLs) in the name of “radical transparency” is ...

Pfizer’s chief strategist, Andrew Baum, M.D., is leaving his post two years after pivoting from a career-long tenure as a ...